Patienterne bør monitoreres tæt under dosiseskaleringen, 51 da der er mulighed for øget forekomst af bivirkninger ved højere doseringer.
Patients should be monitored closely following dose escalation given the potential for an increased incidence of adverse reactions at higher dosages.